{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:37:35Z","timestamp":1790901455653,"version":"4.1.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1093\/jac\/dki448","type":"journal-article","created":{"date-parts":[[2005,12,13]],"date-time":"2005-12-13T01:33:09Z","timestamp":1134437589000},"page":"176-189","source":"Crossref","is-referenced-by-count":153,"title":["Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"57","author":[{"given":"Mical","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Leibovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,12,12]]},"reference":[{"key":"key\n\t\t\t\t20171010191641_B1","doi-asserted-by":"crossref","unstructured":"Bodey GP, Elting L, Kassamali H et al. Escherichia coli bacteremia in cancer patients. Am J Med1986; 81: 85\u201395.","DOI":"10.1016\/0002-9343(86)90518-8"},{"key":"key\n\t\t\t\t20171010191641_B2","doi-asserted-by":"crossref","unstructured":"Paul M, Soares-Weiser K, Leibovici L. \u03b2-Lactam monotherapy versus \u03b2-lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J2003; 326: 1111\u201315.","DOI":"10.1136\/bmj.326.7399.1111"},{"key":"key\n\t\t\t\t20171010191641_B3","doi-asserted-by":"crossref","unstructured":"Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis2002; 34: 730\u201351.","DOI":"10.1086\/339215"},{"key":"key\n\t\t\t\t20171010191641_B4","doi-asserted-by":"crossref","unstructured":"Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum \u03b2-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin\/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001\u20132002). Diagn Microbiol Infect Dis2003; 47: 435\u201340.","DOI":"10.1016\/S0732-8893(03)00114-7"},{"key":"key\n\t\t\t\t20171010191641_B5","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Jones RN, Marshall SA et al. Inducible amp C \u03b2-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis1997; 28: 211\u201319.","DOI":"10.1016\/S0732-8893(97)00064-3"},{"key":"key\n\t\t\t\t20171010191641_B6","doi-asserted-by":"crossref","unstructured":"Jacoby GA, Munoz-Price LS. The new \u03b2-lactamases. N Engl J Med2005; 352: 380\u201391.","DOI":"10.1056\/NEJMra041359"},{"key":"key\n\t\t\t\t20171010191641_B7","unstructured":"Alderson P, Green S, Higgins JPT et al. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. Appendix & Sons, Ltd; 5b. In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd.; 2004."},{"key":"key\n\t\t\t\t20171010191641_B8","doi-asserted-by":"crossref","unstructured":"Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet1998; 352: 609\u201313.","DOI":"10.1016\/S0140-6736(98)01085-X"},{"key":"key\n\t\t\t\t20171010191641_B9","doi-asserted-by":"crossref","unstructured":"Schulz KF, Chalmers I, Hayes RJ et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995; 273: 408\u201312.","DOI":"10.1001\/jama.273.5.408"},{"key":"key\n\t\t\t\t20171010191641_B10","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. Br Med J2003; 327: 557\u201360.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"key\n\t\t\t\t20171010191641_B11","doi-asserted-by":"crossref","unstructured":"Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol2000; 53: 1119\u201329.","DOI":"10.1016\/S0895-4356(00)00242-0"},{"key":"key\n\t\t\t\t20171010191641_B12","doi-asserted-by":"crossref","unstructured":"Paul M, Yahav D, Fraser A et al. Single-agent antibiotic therapy for the initial, empirical, treatment of febrile neutropenia: comparison of \u03b2-lactams. (Protocol). The Cochrane Database of Systematic Reviews2005, Issue 2. Art. No.: CD005197. doi: 10.1002\/14651858.CD005197.","DOI":"10.1002\/14651858.CD005197"},{"key":"key\n\t\t\t\t20171010191641_B13","doi-asserted-by":"crossref","unstructured":"Anaissie EJ, Fainstein V, Bodey GP et al. Randomized trial of \u03b2-lactam regimens in febrile neutropenic cancer patients. Am J Med1988; 84: 581\u20139.","DOI":"10.1016\/0002-9343(88)90140-4"},{"key":"key\n\t\t\t\t20171010191641_B14","unstructured":"Aoun M, Boogaerts MA, Bosly AJ et al. A multicenter, randomized, prospective, comparative study of cefepime plus vancomycin versus ceftazidime plus vancomycin as empiric therapy in the treatment of febrile episodes in granulocytopenic patients with hematological malignancies. Joint clinical\/statistical review of NDA 50,679\/SE1-002. http:\/\/www.fda.gov\/cder\/foi\/nda\/97\/050679s002.htm (18 September 2005, date last accessed)."},{"key":"key\n\t\t\t\t20171010191641_B15","doi-asserted-by":"crossref","unstructured":"Aparicio J, Oltra A, Llorca C et al. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. Eur J Cancer1996; 32A: 1739\u201343.","DOI":"10.1016\/0959-8049(96)00188-8"},{"key":"key\n\t\t\t\t20171010191641_B16","unstructured":"Bickers J, Gumbart C, Cavalier J et al. A prospective randomized trial of cefoperazone plus sulbactam versus imipenem-cilastatin in febrile neutropenic patients. Clin Res1990; 38: 991A."},{"key":"key\n\t\t\t\t20171010191641_B17","doi-asserted-by":"crossref","unstructured":"Biron P, Fuhrmann C, Cure H et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother1998; 42: 511\u201318.","DOI":"10.1093\/jac\/42.4.511"},{"key":"key\n\t\t\t\t20171010191641_B18","doi-asserted-by":"crossref","unstructured":"Bodey GP, Fainstein V, Elting LS et al. \u03b2-Lactam regimens for the febrile neutropenic patient. Cancer1990; 65: 9\u201316.","DOI":"10.1002\/1097-0142(19900101)65:1<9::AID-CNCR2820650105>3.0.CO;2-C"},{"key":"key\n\t\t\t\t20171010191641_B19","doi-asserted-by":"crossref","unstructured":"Bodey G, Abi-Said D, Rolston K et al. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis1996; 15: 625\u201334.","DOI":"10.1007\/BF01691147"},{"key":"key\n\t\t\t\t20171010191641_B20","unstructured":"Bohme A, Shah PM, Stille W et al. Piperacillin\/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res1998; 3: 324\u201330."},{"key":"key\n\t\t\t\t20171010191641_B21","doi-asserted-by":"crossref","unstructured":"Boogaerts MA, Demuynck H, Mestdagh N et al. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother1995; 36: 185\u2013200.","DOI":"10.1093\/jac\/36.1.185"},{"key":"key\n\t\t\t\t20171010191641_B22","unstructured":"Bow EJ, Noskin GA, Schwarer AP et al. Efficacy of piperacillin\/tazobactam as initial empiric therapy of febrile neutropenia in patients with hematologic malignancy. In: Abstracts of the Forty-fifth Annual Meeting of the American Society of Hematology, San Diego, CA, 2003. Abstract 1000. American Society of Hematology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010191641_B23","unstructured":"Bow EJ, Schwarer AP, Laverdiere M et al. Efficacy of piperacillin\/tazobactam as initial empiric therapy of febrile neutropenia in patients with hematologic malignancy. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract L-114. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010191641_B24","unstructured":"Noskin GA, Vesole D, Szer J et al. Multicenter efficacy and safety study of piperacillin\/tazobactam as empiric treatment for neutropenic fever in patients with hematologic malignancies. In: Abstracts of the Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, 2003. Abstract no. 373. Infectious Diseases Society of America, Alexandria, VA, USA."},{"key":"key\n\t\t\t\t20171010191641_B25","doi-asserted-by":"crossref","unstructured":"Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother2000; 34: 989\u201395.","DOI":"10.1345\/aph.10001"},{"key":"key\n\t\t\t\t20171010191641_B26","doi-asserted-by":"crossref","unstructured":"Cherif H, Bjorkholm M, Engervall P et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis2004; 36: 593\u2013600.","DOI":"10.1080\/00365540410017590"},{"key":"key\n\t\t\t\t20171010191641_B27","doi-asserted-by":"crossref","unstructured":"Chuang YY, Hung IJ, Yang CP et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J2002; 21: 203\u20139.","DOI":"10.1097\/00006454-200203000-00009"},{"key":"key\n\t\t\t\t20171010191641_B28","unstructured":"Cornely OA, Reichert D, Buchheidt D et al. Three-armed multicenter randomized study on the empiric treatment of neutropenic fever in a high risk patient population (PEG Study III). In: Abstracts of the Forty-first Interscience Conference on Antimicrobials Agents and Chemotherapy, Chicago, IL, 2001. Abstract L-775, p. 446. American Society for Microbiology, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171010191641_B29","doi-asserted-by":"crossref","unstructured":"Feld R, DePauw B, Berman S et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol2000; 18: 3690\u20138.","DOI":"10.1200\/JCO.2000.18.21.3690"},{"key":"key\n\t\t\t\t20171010191641_B30","doi-asserted-by":"crossref","unstructured":"Figuera A, Rivero N, Pajuelo F et al. Initial empiric therapy of febrile neutropenia with antibiotic monotherapy. Piperacillin\/tazobactam versus imipenem\/cilastatin (1994-1996). Med Clin2001; 116: 610\u201311.","DOI":"10.1016\/S0025-7753(01)71921-5"},{"key":"key\n\t\t\t\t20171010191641_B31","doi-asserted-by":"crossref","unstructured":"Fleischhack G, Hartmann C, Simon A et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother2001; 47: 841\u201353.","DOI":"10.1093\/jac\/47.6.841"},{"key":"key\n\t\t\t\t20171010191641_B32","doi-asserted-by":"crossref","unstructured":"Freifeld AG, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol1995; 13: 165\u201376.","DOI":"10.1200\/JCO.1995.13.1.165"},{"key":"key\n\t\t\t\t20171010191641_B33","unstructured":"Glauser M, Dekker AW, Van Marwijkkooy M et al. A multicenter comparative study of cefepime vs. ceftazidime as empiric therapy in the treatment of febrile episodes in neutropenic patients. Joint clinical\/statistical review of NDA 50,679\/SE1-002. http:\/\/www.fda.gov\/cder\/foi\/nda\/97\/050679s002.htm (18 September, 2005, date last accessed)."},{"key":"key\n\t\t\t\t20171010191641_B34","doi-asserted-by":"crossref","unstructured":"Kebudi R, Gorgun O, Ayan I et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol2001; 36: 434\u201341.","DOI":"10.1002\/mpo.1107"},{"key":"key\n\t\t\t\t20171010191641_B35","doi-asserted-by":"crossref","unstructured":"Kutluk T, Kurne O, Akyuz C et al. Cefepime vs. meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer2004; 42: 284\u20136.","DOI":"10.1002\/pbc.10442"},{"key":"key\n\t\t\t\t20171010191641_B36","doi-asserted-by":"crossref","unstructured":"Liang R, Yung R, Chiu E et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother1990; 34: 1336\u201341.","DOI":"10.1128\/AAC.34.7.1336"},{"key":"key\n\t\t\t\t20171010191641_B37","doi-asserted-by":"crossref","unstructured":"Lindblad R, Rodjer S, Adriansson M et al. Empiric monotherapy for febrile neutropenia\u2014a randomized study comparing meropenem with ceftazidime. Scand J Infect Dis1998; 30: 237\u201343.","DOI":"10.1080\/00365549850160864"},{"key":"key\n\t\t\t\t20171010191641_B38","doi-asserted-by":"crossref","unstructured":"Mustafa MM, Carlson L, Tkaczewski I et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J2001; 20: 362\u20139.","DOI":"10.1097\/00006454-200103000-00036"},{"key":"key\n\t\t\t\t20171010191641_B39","unstructured":"Oppenheim BA, Morgenstern GR, Chang J et al. Safety and efficacy of piperacillin\/tazobactam versus meropenem in the treatment of febrile neutropenia. J Infect2001; 43: A67."},{"key":"key\n\t\t\t\t20171010191641_B40","doi-asserted-by":"crossref","unstructured":"Raad, II, Escalante C, Hachem RY et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer2003; 98: 1039\u201347.","DOI":"10.1002\/cncr.11613"},{"key":"key\n\t\t\t\t20171010191641_B41","unstructured":"Ramphal R, Haddow A, McCracken GH. A comparative study of cefepime vs. ceftazidime in the treatment of adult cancer patients with fever and neutropenia. Joint clinical\/statistical review of NDA 50,679\/SE1-002. http:\/\/www.fda.gov\/cder\/foi\/nda\/97\/050679s002.htm (18 September, 2005, date last accessed)."},{"key":"key\n\t\t\t\t20171010191641_B42","doi-asserted-by":"crossref","unstructured":"Rolston KV, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med1992; 152: 283\u201391.","DOI":"10.1001\/archinte.1992.00400140037010"},{"key":"key\n\t\t\t\t20171010191641_B43","unstructured":"Shichmanter R, Miller E, Shtalrid M et al. Empiric antibiotic treatment of adults with neutropenic fever in a general internal medicine ward. In: Abstracts of the Fourteenth European Congress of Clinical Microbiology and Infectious Diseases, Prague, 2004. Abstract P1452. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland."},{"key":"key\n\t\t\t\t20171010191641_B44","doi-asserted-by":"crossref","unstructured":"Tamura K, Matsuoka H, Tsukada J et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol2002; 71: 248\u201355.","DOI":"10.1002\/ajh.10236"},{"key":"key\n\t\t\t\t20171010191641_B45","doi-asserted-by":"crossref","unstructured":"Vandercam B, Gerain J, Humblet Y et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol2000; 79: 152\u20137.","DOI":"10.1007\/s002770050571"},{"key":"key\n\t\t\t\t20171010191641_B46","doi-asserted-by":"crossref","unstructured":"Wang FD, Liu CY, Hsu HC et al. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy1999; 45: 370\u20139.","DOI":"10.1159\/000007228"},{"key":"key\n\t\t\t\t20171010191641_B47","doi-asserted-by":"crossref","unstructured":"Winston DJ, Bartoni K, Bruckner DA et al. Randomized comparison of sulbactam\/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis1998; 26: 576\u201383.","DOI":"10.1086\/514578"},{"key":"key\n\t\t\t\t20171010191641_B48","doi-asserted-by":"crossref","unstructured":"Hess U, Bohme C, Rey K et al. Monotherapy with piperacillin\/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer1998; 6: 402\u20139.","DOI":"10.1007\/s005200050184"},{"key":"key\n\t\t\t\t20171010191641_B49","doi-asserted-by":"crossref","unstructured":"Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet2004; 364: 2021\u20139.","DOI":"10.1016\/S0140-6736(04)17514-4"},{"key":"key\n\t\t\t\t20171010191641_B50","doi-asserted-by":"crossref","unstructured":"Psaty BM, Furberg CD. COX-2 inhibitors\u2014lessons in drug safety. N Engl J Med2005; 352: 1133\u20135.","DOI":"10.1056\/NEJMe058042"},{"key":"key\n\t\t\t\t20171010191641_B51","unstructured":"Sanders CC. Cefepime: the next generation? Clin Infect Dis1993; 17: 369\u201379."},{"key":"key\n\t\t\t\t20171010191641_B52","doi-asserted-by":"crossref","unstructured":"Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect2002; 8: 823\u20135.","DOI":"10.1046\/j.1469-0691.2002.00492.x"},{"key":"key\n\t\t\t\t20171010191641_B53","doi-asserted-by":"crossref","unstructured":"Egger M, Altman DG, Smith GD. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Books; 2001.","DOI":"10.1002\/9780470693926"},{"key":"key\n\t\t\t\t20171010191641_B54","doi-asserted-by":"crossref","unstructured":"Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol2000; 18: 3038\u201351.","DOI":"10.1200\/JCO.2000.18.16.3038"},{"key":"key\n\t\t\t\t20171010191641_B55","doi-asserted-by":"crossref","unstructured":"Ortega M, Rovira M, Filella X et al. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol2004; 126: 372\u20136.","DOI":"10.1111\/j.1365-2141.2004.05053.x"},{"key":"key\n\t\t\t\t20171010191641_B56","doi-asserted-by":"crossref","unstructured":"Reuter S, Kern WV, Sigge A et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis2005; 40: 1087\u201393.","DOI":"10.1086\/428732"},{"key":"key\n\t\t\t\t20171010191641_B57","doi-asserted-by":"crossref","unstructured":"Paul M, Borok S, Fraser A et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother2005; 55: 436\u201344.","DOI":"10.1093\/jac\/dki028"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/57\/2\/176\/17429083\/dki448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T14:30:40Z","timestamp":1586615440000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/57\/2\/176\/804672\/Empirical-antibiotic-monotherapy-for-febrile"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,12]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,12,12]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki448","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,2]]},"published":{"date-parts":[[2005,12,12]]}}}